Medtech specialist Acarix AB names Christian Lindholm as Interim CEO

Acarix AB (publ) (“Acarix”), developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of the company’s current CFO, Christian Lindholm as interim Chief Executive Officer. Lindholm replaces CEO Søren Rysholt Christiansen who announced his resignation on November 6th, 2017.

“I am confident that Christian, who has been with the company and served in the management team as CFO since June 2017, will ensure a seamless transition of the leadership until a permanent CEO has been established”, said Dr. Werner Braun, chairman of Acarix.

Christian Lindholm will serve as interim Chief Executive Officer while the Board of Directors continue the work to establish a permanent solution.
Christian Lindholm has during the last 17 years held positions as CFO within both private and listed companies. Prior to joining Acarix in 2017, Christian was CFO at Doro AB and TFS International AB.

Dr. Werner Braun, Chairman of the Board, E-mail:, Phone: +49 151 70 131 343
Christian Lindholm, interim Chief Executive Officer, E-mail:, Phone: +46 705 118 333

Notes to editors:
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team.

The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patientspecific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.


About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit